146 related articles for article (PubMed ID: 25217085)
1. [Successful therapy of metastatic basal cell carcinoma with vismodegib].
Zutt M; Mazur F; Bergmann M; Lemke AJ; Kaune KM
Hautarzt; 2014 Nov; 65(11):974-7. PubMed ID: 25217085
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.
Tang JC; Hanke CW; Caro I
J Drugs Dermatol; 2018 May; 17(5):506-508. PubMed ID: 29742180
[TBL] [Abstract][Full Text] [Related]
4. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
[TBL] [Abstract][Full Text] [Related]
5. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
[TBL] [Abstract][Full Text] [Related]
6. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
[TBL] [Abstract][Full Text] [Related]
7. Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.
Routt E; Ratner D
Dermatol Surg; 2020 Aug; 46(8):1109-1112. PubMed ID: 31274526
[No Abstract] [Full Text] [Related]
8. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
Keserü M; Green S; Dulz S
Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
[No Abstract] [Full Text] [Related]
9. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
Chanu P; Musib L; Wang X; Cheeti S; Girish S; Bruno R; Lu T; Reddy J; Jin JY; Caro I
J Invest Dermatol; 2021 Apr; 141(4):930-933. PubMed ID: 32976880
[No Abstract] [Full Text] [Related]
10. BCC and vismodegib: can we treat and remold at the same time?
Russo F; Mancini V; Trovato E; Fimiani M; Taddeucci P
G Ital Dermatol Venereol; 2020 Feb; 155(1):119-120. PubMed ID: 29781264
[No Abstract] [Full Text] [Related]
11. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
12. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
[TBL] [Abstract][Full Text] [Related]
13. Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment.
Feigenbaum L; Scott BL; Moye MS; Nijhawan RI
Dermatol Surg; 2017 Jul; 43(7):989-991. PubMed ID: 28002101
[No Abstract] [Full Text] [Related]
14. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience.
Scalvenzi M; Villani A; Costa C; Cappello M
Dermatol Ther; 2019 Jul; 32(4):e12971. PubMed ID: 31124200
[No Abstract] [Full Text] [Related]
17. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
Angnardo L; Humeda Y; Alexandraki I; Wolfe CM; Cognetta AB
J Drugs Dermatol; 2021 May; 20(5):552-554. PubMed ID: 33938701
[TBL] [Abstract][Full Text] [Related]
18. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
Papastefanou VP; René C
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.
Dreno B; Basset-Seguin N; Caro I; Yue H; Schadendorf D
Oncologist; 2014 Aug; 19(8):790-6. PubMed ID: 25001266
[TBL] [Abstract][Full Text] [Related]
20. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.
Iarrobino A; Messina JL; Kudchadkar R; Sondak VK
J Am Acad Dermatol; 2013 Jul; 69(1):e33-4. PubMed ID: 23768306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
